Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer

Cancer statistics, 2018

Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

HMDB 3.0—The Human Metabolome Database in 2013

Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou-Feunang, Y., Mandal, R., Aziat, F., Dong, E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1065 · Cited by 2,845 · see citing works

Metformin and reduced risk of cancer in diabetic patients

Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · see citing works

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · see citing works

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy

Ashton, T. M., McKenna, W. G., Kunz‐Schughart, L. A., & Higgins, G. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3070 · Cited by 1,144 · see citing works

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · see citing works

p53 and metabolism

Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · see citing works

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0441 · Cited by 912 · see citing works

A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients

Schleucher, J., Schwendinger, M. G., Sattler, M., Schmidt, P. M., Schedletzky, O., Glaser, S. J., S�rensen, O., & Griesinger, C. (1994) · Journal of Biomolecular NMR · doi:10.1007/bf00175254 · Cited by 808 · see citing works

MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells

Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722 · see citing works

KRAS: feeding pancreatic cancer proliferation

Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675 · see citing works

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · see citing works

Mechanisms and Implications of Metabolic Heterogeneity in Cancer

Kim, J., & DeBerardinis, R. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.013 · Cited by 606 · see citing works

Targeting the MAPK pathway in KRAS-driven tumors

Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512 · see citing works

Oncogenic KRAS signalling in pancreatic cancer

Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504 · see citing works

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398 · see citing works

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 394 · see citing works

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Kordes, S., Pollak, M., Zwinderman, A. H., Mathôt, R. A. A., Weterman, M. J., Beeker, A., Punt, C. J. A., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 387 · see citing works

PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers

Gentric, G., Kieffer, Y., Mieulet, V., Goundiam, O., Bonneau, C., Némati, F., Hurbain, I., Raposo, G., Popova, T. G., Stern, M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.002 · Cited by 311 · see citing works

Sparse canonical methods for biological data integration: application to a cross-platform study

Cao, K. L., Martin, P. G. P., Robert-Granié, C., & Besse, P. C. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-34 · Cited by 284 · see citing works

Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States

Jia, D., Park, J. E., Jung, K., Levine, H., & Kaipparettu, B. A. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 275 · see citing works

Heterogeneity in Cancer Metabolism: New Concepts in an Old Field

Gentric, G., Mieulet, V., & Mechta‐Grigoriou, F. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 237 · see citing works

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

Nicolle, R., Blum, Y., Marisa, L., Loncle, C., Gayet, O., Moutardier, V., Turrini, O., Giovannini, M. F., Bian, B., Bigonnet, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.003 · Cited by 199 · see citing works

Exploiting the bad eating habits of Ras-driven cancersPreprint

White, E. (2013) · Genes & Development · doi:10.1101/gad.228122.113 · Cited by 177 · see citing works

Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia

Shi, G., DiRenzo, D., Qu, C., Barney, D., Miley, D., & Konieczny, S. F. (2013) · Oncogene · doi:10.1038/onc.2012.210 · Cited by 162 · see citing works

The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance

Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 151 · see citing works

Sensitivity improvement in isotropic mixing (TOCSY) experiments

Cavanagh, J., & Rance, M. (1990) · Journal of Magnetic Resonance (1969) · doi:10.1016/0022-2364(90)90109-m · Cited by 143 · see citing works

Metabolism addiction in pancreatic cancer

Blum, R., & Kloog, Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.38 · Cited by 134 · see citing works

Mitochondrial Morphofunction in Mammalian Cells

Bulthuis, E. P., Adjobo-Hermans, M. J. W., Willems, P. H. G. M., & Koopman, W. J. H. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7534 · Cited by 128 · see citing works

Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases

Giachin, G., Bouverot, R., Acajjaoui, S., Pantalone, S., & Soler‐López, M. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00043 · Cited by 117 · see citing works

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment

Pollak, M. (2014) · Nature Medicine · doi:10.1038/nm.3596 · Cited by 115 · see citing works

Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation

Wu, H., Ying, M., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9746 · Cited by 109 · see citing works

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

Nicolle, R., Blum, Y., Duconseil, P., Vanbrugghe, C., Brandone, N., Poizat, F., Roques, J., Bigonnet, M., Gayet, O., Rubis, M., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102858 · Cited by 93 · see citing works

Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin

Rajeshkumar, N. V., Yabuuchi, S., Pai, S. G., Oliveira, E. D., Kamphorst, J. J., Rabinowitz, J. D., Tejero, H., Al‐Shahrour, F., Hidalgo, M. M., Maitra, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1115 · Cited by 90 · see citing works

Metabolic Dependencies in Pancreatic Cancer

Gohar, A. V., Zarei, M., Brody, J. R., & Winter, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00617 · Cited by 87 · see citing works

Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts

Kisfalvi, K., Moro, A., Sinnett‐Smith, J. W., Eibl, G., & Rozengurt, E. (2013) · Pancreas · doi:10.1097/mpa.0b013e31827aec40 · Cited by 86 · see citing works

Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts

Bian, B., Bigonnet, M., Gayet, O., Loncle, C., Maignan, A., Gilabert, M., Moutardier, V., Garcia, S., Turrini, O., Delpéro, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606975 · Cited by 71 · see citing works

Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines

Kovalenko, I., Glasauer, A., Schöckel, L., Sauter, D. R. P., Ehrmann, A., Sohler, F., Hägebarth, A., Novak, I., & Christian, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160658 · Cited by 54 · see citing works

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer

Qian, W., Li, J., Chen, K., Jiang, Z., Cheng, L., Zhou, C., Yan, B., Cao, J., Ma, Q., & Duan, W. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.046 · Cited by 48 · see citing works

Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification

Bhaw‐Luximon, A., & Jhurry, D. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2178-4 · Cited by 34 · see citing works

A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor

Gayet, O., Loncle, C., Duconseil, P., Gilabert, M., López‐Millán, B., Moutardier, V., Turrini, O., Calvo, E. L., Ewald, J., Giovannini, M. F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2685 · Cited by 28 · see citing works

Evolution of novel therapeutic options for pancreatic cancer

Saluja, A. K., Dudeja, V., & Banerjee, S. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000298 · Cited by 20 · see citing works

Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications

Greene, J. P., Segaran, A., & Lord, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.002 · Cited by 212 · see citing works

The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint

Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 133 · see citing works

Role of hypoxia in the tumor microenvironment and targeted therapy

Chen, G., Wu, K., Li, H., Xia, D., & He, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961637 · Cited by 141 · see citing works

Cancer resistance and metastasis are maintained through oxidative phosphorylation

Uslu, C., Kapan, E., & Lyakhovich, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216705 · Cited by 103 · see citing works

Metabolic flux analysis of 3D spheroids reveals significant differences in glucose metabolism from matched 2D cultures of colorectal cancer and pancreatic ductal adenocarcinoma cell lines

Tidwell, T., Røsland, G. V., Tronstad, K. J., Søreide, K., & Hagland, H. R. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00285-w · Cited by 85 · see citing works

Autophagy is a major metabolic regulator involved in cancer therapy resistance

Poillet-Perez, L., Sarry, J., & Joffre, C. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109528 · Cited by 82 · see citing works

OXPHOS-targeting drugs in oncology: new perspectives

Kalyanaraman, B., Cheng, G., Hardy, M., & You, M. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2261631 · Cited by 78 · see citing works

Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components

Bahar, E., Han, S., Kim, J., & Yoon, H. (2022) · Cancers · doi:10.3390/cancers14061462 · Cited by 66 · see citing works

Targeting Redox Metabolism in Pancreatic Cancer

Hadi, N. A., Reyes‐Castellanos, G., & Carrier, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041534 · Cited by 62 · see citing works

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

Jain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 59 · see citing works

OXPHOS inhibitors, metabolism and targeted therapies in cancer

Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59 · see citing works

Acidosis orchestrates adaptations of energy metabolism in tumors

Groessl, S., Kalis, R., Snaebjornsson, M. T., Wambach, L., Haider, J., Andersch, F., Schulze, A., Palm, W., & Zuber, J. A. (2025) · Science · doi:10.1126/science.adp7603 · Cited by 54 · see citing works

Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis

Chen, Z., Ho, I.-L., Soeung, M., Yen, E.-Y., Liu, J., Liang, Y., Rose, J. L., Srinivasan, S., Jiang, S., Chang, Q., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37924-9 · Cited by 50 · see citing works

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

Kaoutari, A. E., Fraunhoffer, N. A., Hoare, O., Teyssedou, C., Soubeyran, P., Gayet, O., Roques, J., Lomberk, G. A., Urrutia, R. A., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103332 · Cited by 45 · see citing works

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment

Huang, C., Bian, A., Zhou, W., Miao, Y., Ye, J., Li, J., He, P., Zhang, Q., Sun, Y., Sun, Z., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01440 · Cited by 43 · see citing works

Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target

Duan, H., Ren, J., Wei, S., Yang, Z., Li, C., Wang, Z., Li, M., Wei, Z., Liu, Y., Wang, X., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01410-8 · Cited by 44 · see citing works

Mitochondria Deregulations in Cancer Offer Several Potential Targets of Therapeutic Interventions

Musicco, C., Signorile, A., Pesce, V., Polosa, P. L., & Cormio, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310420 · Cited by 43 · see citing works

Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives

Zhou, Y., Zou, J., Xu, J. B., Zhou, Y., Cen, X., & Zhao, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115219 · Cited by 40 · see citing works

Gold(III)-P-chirogenic complex induces mitochondrial dysfunction in triple-negative breast cancer

Olelewe, C., Kim, J. H., Ofori, S., Mertens, R. T., Gukathasan, S., & Awuah, S. G. (2022) · iScience · doi:10.1016/j.isci.2022.104340 · Cited by 39 · see citing works

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors

Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 37 · see citing works

Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?

McCann, C. K., & Kerr, E. M. (2021) · Cancers · doi:10.3390/cancers13133351 · Cited by 35 · see citing works

Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment

He, P., Bian, A., Miao, Y., Jin, W., Chen, H., He, J., Li, L., Sun, Y., Ye, J., Liu, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01554 · Cited by 34 · see citing works

Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review)

Zuzčák, M., & Trnka, J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5383 · Cited by 33 · see citing works

Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine

Wu, B., Wang, Z., Liu, J., Li, N., Wang, X., Bai, H., Wang, C., Shi, J. Y., Zhang, S., Song, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54963-y · Cited by 30 · see citing works

Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer

Amrutkar, M., & Gladhaug, I. P. (2021) · Cancers · doi:10.3390/cancers13040601 · Cited by 30 · see citing works

Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution

Monberg, M. E., Geiger, H., Lee, J. J., Sharma, R., Semaan, A., Bernard, V., Wong, J., Wang, F., Liang, S., Swartzlander, D. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31376-3 · Cited by 30 · see citing works

Metabolic landscapes in sarcomas

MIALLOT, R., Galland, F., Millet, V., Blay, J., & Naquet, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01125-y · Cited by 27 · see citing works

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction

Lee, D. E., Kang, H. W., Kim, S. Y., Kim, M., Jeong, J. W., Hong, W. C., Fang, S., Kim, H. S., Lee, Y. S., Kim, H. J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934746 · Cited by 29 · see citing works

Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer

Sela, Y., Li, J., Maheswaran, S., Norgard, R. J., Yuan, S., Hubbi, M. E., Doepner, M., Xu, J. P., Ho, E. S., Mesaros, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0431 · Cited by 27 · see citing works

Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer

Deng, M., Zhou, Z., Chen, J., Li, X., Liu, Z., Ye, J., Wei, W., Wang, N., Peng, Y., Luo, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202408599 · Cited by 26 · see citing works

SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells

Kim, M., Hong, W. C., Kang, H. W., Kim, J. H., Lee, D., Cheong, J., Jung, H., Kwon, W., Jang, J., Kim, H. J., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07476-5 · Cited by 26 · see citing works

Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism

Fujiwara‐Tani, R., Sasaki, T., Takagi, T., Mori, S., Kishi, S., Nishiguchi, Y., Ohmori, H., Fujii, K., & Kuniyasu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147824 · Cited by 26 · see citing works

OXPHOS inhibition overcomes chemoresistance in triple negative breast cancer

Uslu, C., Kapan, E., & Lyakhovich, A. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103637 · Cited by 25 · see citing works

Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORγ represents an effective therapeutic opportunity in osteosarcoma

Zheng, J., Wang, Q., Chen, J., Cai, G., Zhang, Z., Zou, H., Zou, J. X., Liu, Q., Ji, S., Shao, G., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101519 · Cited by 25 · see citing works

Metabolic plasticity in pancreatic cancer: The mitochondrial connection

Noemi, G., Abbo, D., Anastasia, B., Costamagna, A., Porporato, P. E., & Martini, M. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102089 · Cited by 24 · see citing works

A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study

Wu, Y., Zeng, H., Yu, Q., Huang, H., Fervers, B., Chen, Z., & Lu, L. (2021) · Cancers · doi:10.3390/cancers13112565 · Cited by 24 · see citing works

Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles

Ali, H. A., Karasinska, J. M., Topham, J. T., Johal, D., Kalloger, S. E., Metcalfe, A., Warren, C., Miyagi, A., Tao, L. V., Kevorkova, M., et al. (2024) · Cancer & Metabolism · doi:10.1186/s40170-024-00357-z · Cited by 23 · see citing works

Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting

Pan, B., Hsu, C.-C., Wu, H., Chen, Y.-R., Zhou, X., Wang, S., Li, C., & Lin, H.-K. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01167-1 · Cited by 24 · see citing works

Mitochondrial Elongation and OPA1 Play Crucial Roles during the Stemness Acquisition Process in Pancreatic Ductal Adenocarcinoma

Carmona‐Carmona, C. A., Pozza, E. D., Ambrosini, G., Cisterna, B., Palmieri, M., Decimo, I., Cuezva, J. M., Bottani, E., & Dando, I. (2022) · Cancers · doi:10.3390/cancers14143432 · Cited by 23 · see citing works

Clinicopathological significance of unraveling mitochondrial pathway alterations in non‐small‐cell lung cancer

Hertweck, K. L., Vikramdeo, K. S., Galeas, J. N., Marbut, S. M., Pramanik, P., Yunus, F., Singh, S., Singh, A. P., & Dasgupta, S. (2023) · The FASEB Journal · doi:10.1096/fj.202201724rr · Cited by 22 · see citing works

Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression

Ogunleye, A. O., Nimmakayala, R. K., Batra, S. K., & Ponnusamy, M. P. (2023) · Stem Cells · doi:10.1093/stmcls/sxad017 · Cited by 21 · see citing works

Genetics of enzymatic dysfunctions in metabolic disorders and cancer

Mahé, M., Rios-Fuller, T. J., Karolin, A., & Schneider, R. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1230934 · Cited by 21 · see citing works

Targeting mitochondrial dysfunctions in pancreatic cancer evokes new therapeutic opportunities

Sarwar, A., Zhu, M., Su, Q., Zhu, Z., Yang, T., Chen, Y., Peng, X., & Zhang, Y. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103858 · Cited by 20 · see citing works

Mitochondrial ATP synthase inhibitory factor 1 interacts with the p53–cyclophilin D complex and promotes opening of the permeability transition pore

Guo, L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101858 · Cited by 21 · see citing works

MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression

Chen, J., Zheng, Q., Hicks, J. L., Trabzonlu, L., Özbek, B., Jones, T., Vaghasia, A. M., Larman, T., Wang, R., Markowski, M. C., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.169868 · Cited by 18 · see citing works

hnRNPH1 maintains mitochondrial homeostasis by establishing NRF1/DRP1 retrograde signaling under mitochondrial stress

Zhao, L., Zou, X., Deng, J., Sun, B., Li, Y., Zhao, L., Zhao, H., Zhang, X., Yuan, X., Zhao, X., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01331-4 · Cited by 18 · see citing works

Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo

Reyes‐Castellanos, G., Hadi, N. A., Gallardo-Arriaga, S., Masoud, R., Garcia, J., Lac, S., Kaoutari, A. E., Gicquel, T., Planque, M., Fendt, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106899 · Cited by 16 · see citing works

Targeting Hypoxia: Revival of Old Remedies

Vilaplana‐Lopera, N., Besh, M., & Moon, E. J. (2021) · Biomolecules · doi:10.3390/biom11111604 · Cited by 17 · see citing works

Mutations of the Electron Transport Chain Affect Lifespan and ROS Levels in C. elegans

Ősz, F., Nazir, A., Takács‐Vellai, K., & Farkas, Z. (2025) · Antioxidants · doi:10.3390/antiox14010076 · Cited by 16 · see citing works

Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers

Moss, D., McCann, C. K., & Kerr, E. M. (2022) · Science Signaling · doi:10.1126/scisignal.abj3490 · Cited by 15 · see citing works

Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

Dash, S., Ueda, T., Komuro, A., Honda, M., Sugisawa, R., & Okada, H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06531-x · Cited by 15 · see citing works

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

Konaté, M. M., Krushkal, J., Li, M., Chen, L., Kotliarov, Y., Palmisano, A., Pauly, R., Xie, Q., Williams, P. M., McShane, L. M., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05528-6 · Cited by 16 · see citing works

Mitochondrial DNA and MitomiR Variations in Pancreatic Cancer: Potential Diagnostic and Prognostic Biomarkers

Moro, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189692 · Cited by 15 · see citing works

Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia modelPreprint

Gicquel, T., Marchianò, F., Reyes‐Castellanos, G., Audebert, S., Camoin, L., Habermann, B. H., Giannesini, B., & Carrier, A. (2024) · eLife · doi:10.7554/elife.93312 · Cited by 15 · see citing works

PAX fusion proteins deregulate gene networks controlling mitochondrial translation in pediatric rhabdomyosarcoma

Kalita, B., Martínez-Cebrián, G., McEvoy, J. D., Allensworth, M. L., Knight, M., Magli, A., Perlingeiro, R. C. R., Dyer, M. A., Stewart, E. A., & Dynlacht, B. D. (2024) · Cell · doi:10.1016/j.cell.2025.03.008 · Cited by 14 · see citing works

Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives

Zhang, Y., Li, W., Niu, J., Fan, Z., Li, X., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586959 · Cited by 14 · see citing works

Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma

Heid, I., Münch, C., Karakaya, S., Lueong, S., Winkelkotte, A. M., Liffers, S. T., Godfrey, L., Cheung, P. F., Savvatakis, K., Topping, G. J., et al. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00298-5 · Cited by 14 · see citing works

Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Wang, Z., Wu, B., Nie, G., Wei, J., & Li, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216138 · Cited by 14 · see citing works

EVT‐701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti‐tumor activity in models of solid cancers

Yolba, R. L., Visentin, V., Hervé, C., Chiche, J., Ricci, J., Meneyrol, J., Paillasse, M. R., & Alet, N. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.854 · Cited by 13 · see citing works

Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation

Solta, A., Ernhofer, B., Boettiger, K., Lang, C., Megyesfalvi, Z., Mendrina, T., Kirchhofer, D., Timelthaler, G., Szeitz, B., Rezeli, M., et al. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00382-6 · Cited by 13 · see citing works

First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer

Xu, Y., Xue, D., Kyani, A., Bankhead, A., Roy, J., Ljungman, M. E., & Neamati, N. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00069 · Cited by 13 · see citing works

Extracellular Matrix Collagen I Differentially Regulates the Metabolic Plasticity of Pancreatic Ductal Adenocarcinoma Parenchymal Cell and Cancer Stem Cell

Tavares‐Valente, D., Cannone, S., Greco, M. R., Carvalho, T. M. A., Baltazar, F., Queirós, O., Agrimi, G., Reshkin, S. J., & Cardone, R. A. (2023) · Cancers · doi:10.3390/cancers15153868 · Cited by 13 · see citing works

Melatonin controls cell proliferation and modulates mitochondrial physiology in pancreatic stellate cells

Estarás, M., Ortiz-Placín, C., Castillejo-Rufo, A., Fernández‐Bermejo, M., Blanco‐Fernández, G., Mateos, J. M., Vara, D., Gonzalez-Cordero, P. L., Chamizo, S., López-Guerra, D., et al. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00930-4 · Cited by 13 · see citing works

Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy

Torresano, L., Santacatterina, F., Domínguez-Zorita, S., Nuevo‐Tapioles, C., Núñez-Salgado, A., Esparza‐Moltó, P. B., González-Llorente, L., Romero-Carramiñana, I., de Arenas, C. N., Sánchez-Garrido, B., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00400-y · Cited by 13 · see citing works

The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma

MIALLOT, R., Millet, V., Roger, A., Fenouil, R., Tardivel, C., Martin, J., Tranchida, F., Shintu, L., BERCHARD, P., Lanza, J. S., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202302200 · Cited by 12 · see citing works

Radiation-triggerable bioreactors enable bioenergetic reprograming of cancer stem cell plasticity via targeted arginine metabolism disruption for augmented radio-immunotherapy

Yao, X., Yang, H., Guo, S., Liu, Y., Zhang, Q., Zhou, Z., Li, M., & Luo, Z. Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123391 · Cited by 12 · see citing works

Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC

Dujardin, P., Baginska, A. K., Urban, S., & Grüner, B. M. (2021) · Cancers · doi:10.3390/cancers13164187 · Cited by 12 · see citing works

Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications

Ohara, Y., Liu, H., Moreno, P., Suzuki, S., & Hussain, S. P. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108946 · Cited by 11 · see citing works

Extensive therapeutic effects, underlying molecular mechanisms and disease treatment prediction of Metformin: a systematic review

Geng, Y., Wang, Z., Xu, X., Sun, X., Dong, X., Luo, Y., & Sun, X. (2023) · Translational research · doi:10.1016/j.trsl.2023.08.001 · Cited by 11 · see citing works

UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect

Caggiano, E. G., & Taniguchi, C. M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10157-4 · Cited by 11 · see citing works

Improved pH-Responsive Release of Phenformin from Low-Defect Graphene Compared to Graphene Oxide

Alhourani, A. H., Førde, J.-L., Eichacker, L. A., Herfindal, L., & Hagland, H. R. (2021) · ACS Omega · doi:10.1021/acsomega.1c03283 · Cited by 11 · see citing works

Tumoral acidosis promotes adipose tissue depletion by fostering adipocyte lipolysis

Lefevre, C., Thibaut, M. M., Loumaye, A., Thissen, J., Neyrinck, A. M., Navez, B., Delzenne, N. M., Féron, O., & Bindels, L. B. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101930 · Cited by 10 · see citing works

Proton-Translocating NADH–Ubiquinone Oxidoreductase: Interaction with Artificial Electron Acceptors, Inhibitors, and Potential Medicines

Grivennikova, V. G., Gladyshev, G. V., Zharova, T. V., & Borisov, V. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413421 · Cited by 10 · see citing works

Label-free spatially maintained measurements of metabolic phenotypes in cells

Hu, L., Wang, N., Bryant, J. D., Liu, L., Xie, L., West, A. P., & Walsh, A. J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1293268 · Cited by 10 · see citing works

HDGF stimulates liver tumorigenesis by enhancing reactive oxygen species generation in mitochondria

Hu, T., Wu, J., Huang, S., Chu, T., Han, A., Shih, T.-W., Chang, Y., Yang, S., Ko, C., Lin, Y., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105335 · Cited by 9 · see citing works

Tailoring metabolic activity assays for tumour-engineered 3D models

Clegg, J., Curvello, R., Gabrielyan, A., Croagh, D. G., Hauser, S., & Loessner, D. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214116 · Cited by 9 · see citing works

Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells

Poles, M., Pacchiana, R., Mortali, C., Cisterna, B., Mullappilly, N., Celesia, A., Danzi, F., Gaspari, M., Cecconi, D., Donadelli, M., et al. (2025) · FEBS Journal · doi:10.1111/febs.70223 · Cited by 9 · see citing works

Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma

Pook, H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13194834 · Cited by 10 · see citing works

Biguanide MC001, a Dual Inhibitor of OXPHOS and Glycolysis, Shows Enhanced Antitumor Activity Without Increasing Lactate Production

Fu, J., Liu, S., Hu, M., Liao, X., Wang, X., Xu, Z., Li, Q., & Quan, J. (2022) · ChemMedChem · doi:10.1002/cmdc.202100674 · Cited by 9 · see citing works

Triphenylphosphonium-Conjugated Palmitic Acid for Mitochondrial Targeting of Pancreatic Cancer Cells: Proteomic and Molecular Evidence

Siragusa, G., Brandi, J., Rawling, T., Murray, M. T., & Cecconi, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126790 · Cited by 8 · see citing works

Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells

Francès, A., Lumeau, A., Béry, N., Gayral, M., Stuani, L., Sorbara, M., Saland, E., Pagan, D., Hanoun, N., Torrisani, J., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06760-y · Cited by 8 · see citing works

Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model

Gicquel, T., Marchianò, F., Reyes‐Castellanos, G., Audebert, S., Camoin, L., Habermann, B. H., Giannesini, B., & Carrier, A. (2024) · eLife · doi:10.7554/elife.93312.2 · Cited by 8 · see citing works

Sonodynamic therapy-based dual blockade of glucose metabolism strategy for pancreatic cancer treatment

Wang, L., Li, J., Zheng, Y., Li, Y., Zhu, Q., Cao, J., & Sun, L. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160180 · Cited by 8 · see citing works

Identification of myoferlin as a mitochondria-associated membranes component required for calcium signaling in PDAC cell lines

Anania, S., Farnir, M., Peiffer, R., Boumahd, Y., Thiry, M., Agirman, F., Maloujahmoum, N., Bellahcène, A., & Peulen, O. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01514-z · Cited by 8 · see citing works

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma

Blázquez‐Encinas, R., Alors‐Pérez, E., Moreno-Montilla, M. T., García‐Vioque, V., Sánchez‐Frías, M., Mafficini, A., Lopez-Canovas, J. L., Bousquet, C., Gahete, M. D., Lawlor, R. T., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00814-3 · Cited by 8 · see citing works

Pak1 dysregulates pyruvate metabolism in PDAC cells by exerting a phosphorylation-mediated regulatory effect on PDHA1

Murugan, S., Srikanth Swamy Swaroop, B., Gopinath, P., Saravanan, R., Sundaram, S., Shanmugasundaram, G., Venkatraman, G., & Rayala, S. K. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108409 · Cited by 7 · see citing works

The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer

Wang, Q., Li, K., Li, L., Qin, L., Qi, Y., Liu, K., Yuan, H., & Lin, P. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1584630 · Cited by 8 · see citing works

Mitochondria-centric lipid metabolism and inter-organelle crosstalk in pancreatic Cancer: Unveiling novel therapies

Wang, R., Gao, C., Fan, Z., Qin, Q., & Zhan, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217965 · Cited by 7 · see citing works

Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression

Jiang, B., Wu, S., Zeng, L., Tang, Y., Luo, L., Ouyang, L., Feng, W., Tan, Y., & Li, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03244-1 · Cited by 7 · see citing works

Oncometabolites in pancreatic cancer: Strategies and its implications

Maiti, A., Mondal, S., Choudhury, S., Bandopadhyay, A., Mukherjee, S., & Sikdar, N. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v14.i4.96005 · Cited by 7 · see citing works

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

Islam, R., Roche, M. E., Lin, Z., Whitaker‐Menezes, D., Diaz‐Barros, V., Serrano, E., Cantarin, M. P. M., Philp, N. J., Mallick, A. B., & Martinez‐Outschoorn, U. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70002 · Cited by 6 · see citing works

Targeting Metabolic Vulnerabilities to Overcome Prostate Cancer Resistance: Dual Therapy with Apalutamide and Complex I Inhibition

Baumgartner, V., Schaer, D., Eberli, D., & Salemi, S. (2023) · Cancers · doi:10.3390/cancers15235612 · Cited by 6 · see citing works

Identification of 6-Fluorine-Substituted Coumarin Analogues as POLRMT Inhibitors with High Potency and Safety for Treatment of Pancreatic Cancer

Zhou, S., Ze, X., Feng, D., Liu, L., Shi, Y., Yu, M., Huang, L., Wang, Y., Men, H., Wu, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01178 · Cited by 6 · see citing works

Progress in antitumor mechanisms and applications of phenformin (Review)

Zhong, Q., Li, D., & Yang, X. (2024) · Oncology Reports · doi:10.3892/or.2024.8810 · Cited by 6 · see citing works

Nuclear TOP1MT Confers Cisplatin Resistance via Pseudogene in HNSCC

Tong, T., Zhai, P., Qin, X., Zhang, Z., Li, C., Guo, H., & L., H. (2024) · Journal of Dental Research · doi:10.1177/00220345241272017 · Cited by 6 · see citing works

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

Alodhaibi, I., Ailawadhi, S., Búrbano, G., O’Brien, P., Buadi, F. K., Hayman, S. R., Kumar, S. K., & Gonsalves, W. I. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.002 · Cited by 6 · see citing works

Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution

Monberg, M. E., Geiger, H. M., Lee, J. J., Sharma, R., Semaan, A., Bernard, V., Wong, J., Wang, F., Liang, S., Swartzlander, D. B., et al. (2022) · RePEc: Research Papers in Economics · Cited by 6 · see citing works

AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?

Sapio, L., Ragone, A., Spina, A., Salzillo, A., & Naviglio, S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.34 · Cited by 6 · see citing works

Matrix composition and glucose availability cooperatively determine cancer spheroid bioenergetics in 3D hydrogels

Guerrero‐López, P., Drobac, G., Silva, E. A., Hagland, H. R., & García‐Aznar, J. M. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00413-2 · Cited by 5 · see citing works

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Hadi, N. A., Reyes‐Castellanos, G., Gicquel, T., Gallardo-Arriaga, S., Cosialls, E., Boët, E., Sarry, J., Masoud, R., Iovanna, J., & Carrier, A. (2025) · Oncogenesis · doi:10.1038/s41389-025-00591-0 · Cited by 5 · see citing works

Targeting mitochondrial metabolism in pancreatic cancer

Reyes‐Castellanos, G. (2021) · doi:10.70675/461953f3z886ez4342za1e2z84c44a9fcaa6

Ciblage du métabolisme mitochondrial dans le cancer du pancréas

Reyes‐Castellanos, G. (2021) · theses.fr (ABES)

Abstract 6803: Targeting mitochondrial complex I overcomes adaptive response to chemotherapy in advanced pancreatic cancer

Attanasio, S., Citron, F., Shah, R., Saj, F., Liu, Z., Ho, I.-L., Yen, E.-Y., Dyke, C. A., Kwon, H. J., Cecchetto, L., et al. (2026) · Cancer Research · doi:10.1158/1538-7445.am2026-6803

Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer

Boukalová, Š., Ezrova, Z., & Neužil, J. (2021) · Oncotarget · doi:10.18632/oncotarget.27976 · Cited by 1 · see citing works

Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma

Ouyang, W., Wang, J., Chen, J., Fang, Z., Wei, T., Qian, J., & Gui, S. (2026) · Translational research · doi:10.1016/j.trsl.2026.09.009